There is evidence that drinking diet soda raises the risk of developing Type 2 diabetes. And certain artificial sweeteners — particularly aspartame — have been implicated in both major and minor health problems, perhaps one reason for the recent drop in sales of diet soda. So it should be no surprise that the beverage industry […]
This past week, the Diabetes Online Community’s been buzzing about Medtronic’s new trade-in offer for its Minimed 530G with Enlite sensor, a pretty brazen move to lure customers away from the competing Dexcom G4 Platinum system.
A roundup on continuous glucose monitor, basal insulin and novel drugs.
Manav Batra, MD, of the University of Buffalo, said during a presentation, that “according to research, testosterone also increases in expression of mediators of signaling and reductions in factors that interfere.”
The bionic pancreas requires patients wear two insulin pumps, one containing insulin and the other containing glucagon, a well as a glucose sensor. A brilliant computerized algorithm hooked to an iPhone is used to pump both insulin and glucagon based on each glucose reading. Will this be enough to overcome the challenges of insulin therapy?
In August 2013, the Ontario provincial government changed their health policy to restrict test strip reimbursement for people with diabetes. Those who are not dependent on insulin therapy will only be reimbursed for 400 test strips a year, while those dependent on insulin therapy will be limited to 3000 strips a year.
Founded in 2011 by Debong, Frank Westermann, Gerald Stangl and Michael Forisch, mySugr wants to help users manage diabetes through its various apps that mix mobile, health and social gaming. But, ultimately, it’s about changing people’s mindset about diabetes and their therapy.
Consumer reviews of the following diabetes products: ONETOUCH ULTRA 2 glucose meter, Verio IQ, ONETOUCH ULTRA MINI glucose meter and T:SLIM INSULIN PUMP.
Two leading endocrinologist organizations have, for the first time in four years, updated their position on who should be able to get access to insulinyes_on_diabetes_tech pumps, while the Diabetes Technology Society (DTS) is launching a post-market surveillance program aimed at ensuring glucose meters and test strips are accurate even long after they’re cleared FDA and […]
The Food and Drug Administration (FDA) has delayed until July 15th making a decision on whether to allow the inhaled insulin Afrezza entry into the American market.
A preliminary study of the effects of mushroom ingestion on health conducted by University at Buffalo nutrition scientists and physiologists has found that healthy male and female subjects who consumed mushrooms with glucose had a significant decrease in glucose responses compared to those who consumed glucose alone.
A recent observational study presented at the 7th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Austria last month suggests patients taking the twice-daily dose may not necessarily achieve improved blood sugar levels or fewer severe hypoglycemic events.
Yet a new study from researchers at the Yale School of Medicine reports that episodes of extremely low blood sugar, or hypoglycemia, are landing diabetics in the hospital too often.
What if glucagon could instead be as easily administered as insulin and utilized by people with diabetes to treat even mild lows? That’s the quest of Xeris, a company that is focusing on biologically friendly ways to make drug mixtures in liquid forms.
Last week, Eli Lilly and Company announced positive top-line results of three completed Phase III clinical trials in patients with type 2 diabetes for basal insulin peglispro (BIL), which is being studied as a once-daily treatment for both type 1 and type 2 diabetes.
One of the most newsy bits we heard more about this weekend was last week’s news that Merck was finally moving forward on smart insulin! Yes, finally, about four years after the Pharma giant acquired SmartCells in late 2010, which was working on this glucose-responsive insulin.
D-blogger and advocate Melissa Lee takes an in-depth look at Snap and explains why it’s one of her favorite D-devices.
We know insulin resistance contributes to Type 2 diabetes. But resistance to another hormone called leptin also contributes big time. Fortunately, we may be able to turn down both kinds of resistance.
Do you feel unsure about what to do or how to bring your blood glucose levels down? Are you scared to go out and do things with friends or family because of the fear that diabetes brings you on a daily basis? If you answered yes to any of these questions, then it is time […]
The objective of this study was to assess the safety and efficacy of adding glimepiride to current insulin therapy in poorly controlled type 2 diabetes – as opposed to using increased insulin dosages.